This study aimed to estimate current direct costs for managing type 2 diabetes mellitus
(T2DM)-related complications including ischaemic heart diseases (IHD), myocardial
infarction (MI), stroke, heart failure (HF), amputation, blindness, renal failure (RF)
requiring haemodialysis (end-stage renal disease) and diabetic foot ulcer in the event year and subsequent year. Initially, diabetes-related complications are defined based on the Malaysian Clinical Practice Guidelines (CPGs) or published literatures while each resource unit was valued using local costing obtained from the public hospital or other sources. The interventions for the management of complications were supported by evidence in the Malaysian CPGs or local literature and confirmed by the physicians related to the field who are working at the public hospital. All costs were converted to the value of USD currency in the year 2016. On the whole, macrovascular diseases incurred the highest management cost with MI employing the highest management cost (USD4,528.37) in the event year, while the management of heart, failure disease incurs the highest management cost at USD524.79 for subsequent year management. End-stage renal disease was associated with the highest annual per-patient costs, with mean first year and subsequent year costs for haemodialysis estimated at USD9,905.37 and USD9,233.89. In studying the costs of managing of diabetes-related complications, these data are vital economic evaluation for diabetes interventions, particularly in managing complications to macrovascular and microvascular functions, as it contributes significantly to the economic burden in Malaysia’s public healthcare; hence significantly affecting the proportion of the overall healthcare costs.
PDB43 COST COMPARISON OF GLICAZIDE MODIFIED-RELEASE AND GENERIC GLICLAZIDE IN PREVENTING END STAGE RENAL DISEASE IN TYPE 2 DIABETES MELLITUS IN THE PUBLIC SECTOR OF MALAYSIA
